Shattuck Labs, Inc. (NASDAQ: STTK) is a Healthcare company (Biotechnology) with a market capitalization of $467M. The Maz Rating grades it against the other companies in its sector.
Shattuck Labs, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.59, Shattuck Labs, Inc. trades at 4.3x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -46.5%, return on invested capital of -36.8% and a free cash flow yield of -10.6%. On the balance sheet: a debt-to-equity ratio of 0.01 and a current ratio of 15.80. Over the past 52 weeks the share price ranged from $1.88 to $8.33, with a beta of 1.13.
Shattuck Labs, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 9 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Shattuck Labs, Inc. (STTK) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 23.5% / 30% · Interest income / Revenue 185500000.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 23.4% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 185500000.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 23.4% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 185500000.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.87% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 68.8% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 185500000.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 94.4% / 33.33% · (Cash+Recv) / Total Assets 94.4% / 33.33% · Interest income / Revenue 185500000.0% / 5% | Fail |
No. As of September 2026, Shattuck Labs, Inc. (STTK) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Shattuck Labs, Inc. is over the AAOIFI limit on Interest income / Revenue.
About 185500000.0% of each dividend: Shattuck Labs, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.